Shanghai Genechem Co Ltd. (Genechem), a discovery company that focuses on novel drug target discovery and development of novel therapeutics, announced on Tuesday that it has implemented a global collaboration with I-Mab (Nasdaq: IMAB), a global biopharmaceutical company.

The collaboration is aimed at developing and commercialising multiple bi-specific antibodies based (BsAb) on a monoclonal antibody developed by Genechem and antibodies selected by I-MAB.

Yueqiong Cao, founder and CEO of Genechem, said, 'This collaboration is the first of many that will leverage Genechem's Good Research Practice (GRP) and CHAMP antibody discovery platform, strong bioinformatic database, as well as strong development expertise of synergistic partners, to deliver globally competitive assets based on innovative targets. We are excited to collaborate with I-Mab, a global leader in Oncology and antibody development, to bring more products to address clinical unmet needs for patients in China and globally.'